Media stories about Synergy Pharmaceuticals (NASDAQ:SGYP) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Synergy Pharmaceuticals earned a news sentiment score of 0.07 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.2667019832501 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern’s analysis:
- Technical data gathered from Synergy Pharmaceuticals Inc. (SGYP) – Wall Street Morning (wallstreetmorning.com)
- Halozyme Therapeutics, Inc. (HALO), Synergy Pharmaceuticals, Inc. (SGYP) – Newburgh Gazette (newburghgazette.com)
- Synergy Pharmaceuticals Inc. (SGYP) Best Stocks with Higher Insider Ownership – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Hot Tickers: Synergy Pharmaceuticals Inc. (SGYP), Genocea Biosciences, Inc. (GNCA) – Market Movers (financialqz.com)
- Synergy Pharmaceuticals (NASDAQ:SGYP) Given Daily News Impact Score of 0.08 (nismagazine.com)
A number of analysts have commented on the company. Canaccord Genuity set a $13.00 price target on Synergy Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, November 12th. HC Wainwright set a $7.00 price objective on Synergy Pharmaceuticals and gave the company a “buy” rating in a report on Monday, December 4th. BidaskClub raised Synergy Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, December 22nd. Cantor Fitzgerald restated a “buy” rating and issued a $10.00 price target on shares of Synergy Pharmaceuticals in a research note on Tuesday, November 21st. Finally, Citigroup lowered Synergy Pharmaceuticals to a “market perform” rating in a research note on Friday, January 5th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. Synergy Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $8.38.
Synergy Pharmaceuticals (NASDAQ:SGYP) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.06. The firm had revenue of $5.01 million for the quarter, compared to analysts’ expectations of $4.53 million. During the same period in the previous year, the business posted ($0.22) EPS. equities research analysts anticipate that Synergy Pharmaceuticals will post -1.03 EPS for the current fiscal year.
In other news, major shareholder Paulson & Co. Inc. sold 8,750,000 shares of Synergy Pharmaceuticals stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $2.82, for a total transaction of $24,675,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.80% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Synergy Pharmaceuticals (NASDAQ:SGYP) Receives Coverage Optimism Rating of 0.07” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://stocknewstimes.com/2018/01/19/synergy-pharmaceuticals-sgyp-receiving-somewhat-positive-press-coverage-study-finds.html.
About Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.
Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.